← Back to Search

mRNA Vaccine

mRNA COVID-19 Vaccines Safety for Previous Vaccine Reactions

Phase 4
Recruiting
Led By James Baker, MD
Research Sponsored by University of Michigan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must be able to understand and provide informed consent
Age over 18
Must not have
Under age 18
Immunocompromised
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 7 days after the vaccine is given
Awards & highlights
No Placebo-Only Group
Pivotal Trial
Drug Has Already Been Approved
All Individual Drugs Already Approved

Summary

This trial is being conducted to see if people who have had bad reactions to COVID-19 vaccines in the past can safely have another dose, or if people with a history of allergies can safely have the vaccine at all.

Who is the study for?
This trial is for adults over 18 who've had adverse reactions to previous mRNA COVID-19 vaccines, allergic reactions without prior vaccination, or issues after a natural COVID infection. They must not be pregnant, immunocompromised, have immune disorders, recent COVID-19 infections or treatments with antibody agents.
What is being tested?
The study tests the safety of an additional dose of Pfizer-BioNTech or Moderna bivalent mRNA COVID-19 vaccine in those with past adverse reactions to vaccines or 'long COVID', and initial doses in those with a history of allergies.
What are the potential side effects?
Potential side effects may include typical vaccine-related responses such as soreness at injection site, fatigue, headache, muscle pain, chills, fever and nausea. Severe allergic reactions are rare but will be closely monitored.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand the study and can give my consent.
Select...
I am over 18 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.
Select...
My immune system is weak.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 7 days after the vaccine is given
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 7 days after the vaccine is given for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of participants with treatment-related allergic reaction adverse events
Secondary study objectives
Number of clinical adverse reaction types (non-allergic)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pfizer-BioNTech mRNA COVID-19 vaccineExperimental Treatment1 Intervention
Subject will receive an initial or additional dose of the Pfizer-BioNTech (Comirnaty) mRNA COVID-19 vaccine

Find a Location

Who is running the clinical trial?

University of MichiganLead Sponsor
1,863 Previous Clinical Trials
6,441,373 Total Patients Enrolled
The Wallace FoundationUNKNOWN
James Baker, MDPrincipal InvestigatorUniversity of Michigan

Media Library

Moderna mRNA COVID-19 vaccine (mRNA Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05212610 — Phase 4
Coronavirus Research Study Groups: Pfizer-BioNTech mRNA COVID-19 vaccine
Coronavirus Clinical Trial 2023: Moderna mRNA COVID-19 vaccine Highlights & Side Effects. Trial Name: NCT05212610 — Phase 4
Moderna mRNA COVID-19 vaccine (mRNA Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05212610 — Phase 4
~0 spots leftby Dec 2024